Clinical Trial Update: Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting [Phase 4]

View source ↗

Summary

Phase 4 trial update describing tolerability of LCZ696 (sacubitril/valsartan) in real-world heart failure with reduced ejection fraction patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hearth Failure With Reduced Ejection Fraction (HFrEF) | Phase 4 | Status: COMPLETED | Results posted: 2019-06-07